T2 Biosystems, Inc. announced it won the “Best New Technology Solution - Diagnostics" award for its T2Bacteria Panel solution in the fourth annual MedTech Breakthrough Awards program.
The awards program, which received thousands of nominations from companies across the globe, “recognizes the top companies, people, platforms and products in the health, fitness and medical technology industries today,” according to its website.
“We’re honored to be recognized by the MedTech Breakthrough Awards and grateful to the judges who recognize the importance of rapid identification of sepsis-causing pathogens in order to effectively and efficiently treat patients with bloodstream infections, which can lead to sepsis,” said John Sperzel, President and Chief Executive Officer of T2 Biosystems.
Sperzel continued, “According to the Centers for Disease Control and Prevention, each year at least 1.7 million adults in America develop sepsis and nearly 270,000 Americans die as a result. But, with swift diagnosis and treatment, which our T2Bacteria Panel helps facilitate, we can help reduce these numbers for patients with bloodstream infections and improve patient outcomes.”
The T2Bacteria Panel, which was FDA cleared in May 2018, can detect sepsis-causing bacterial pathogens directly from whole blood in three to five hours, without the need to wait for a blood culture, which typically takes days to provide results and is not as sensitive. By providing quicker results, the T2Bacteria Panel can help clinicians start patients on the right therapy sooner, which can lead to a series of potential benefits, including improved patient outcomes, better management of antibiotics, reduced length of stay in the hospital and more.
